Compare $BCRX vs $NVAX | Chartloom

Compare

$BCRX vs $NVAX

BioCryst Pharmaceuticals Inc · Novavax Inc

BCRX

BioCryst Pharmaceuticals Inc

NVAX

Novavax Inc

Compare $BCRX vs $NVAX

Comparing BioCryst Pharmaceuticals Inc and Novavax Inc

BCRXBioCryst Pharmaceuticals Inc

NVAXNovavax Inc

BCRXBioCryst Pharmaceuticals Inc

Market cap

$2.17B

P/E (TTM)

—

Forward P/E (NTM)

16.67x

Forward P/S (NTM)

3.13x

Rev growth (TTM)

68.7%

YTD performance

14.0%

52W performance

17.4%

FCF yield

17.9%

NVAXNovavax Inc

Market cap

$2.10B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

10.28x

Rev growth (TTM)

-61.6%

YTD performance

78.8%

52W performance

43.3%

FCF yield

-2.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BCRX

NVAX

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

NVAX

Novavax Inc

Market Cap

BCRX$2.17B

NVAX$2.10B

Enterprise Value

BCRX$2.84B

NVAX$2.20B

Price

BCRX$8.55

NVAX$12.75

P/E Ratio

BCRXN/A

NVAXN/A

P/S Ratio

BCRX2.31x

NVAX5.07x

EV/Sales

BCRX3.02x

NVAX5.32x

EV/EBITDA

BCRX6.85x

NVAX4.05x

P/B Ratio

BCRX62.13x

NVAX45.86x

P/FCF Ratio

BCRX5.59x

NVAXN/A

EV/FCF

BCRX7.32x

NVAX-51.40x

PEG Ratio

BCRXN/A

NVAXN/A

Forward P/E (NTM)

BCRX16.67x

NVAXN/A

Forward P/S (NTM)

BCRX3.13x

NVAX10.28x

Revenue (TTM)

BCRX$941M

NVAX$414M

Revenue Growth (YoY)

BCRX68.7%

NVAX-61.6%

Forward Rev Growth

BCRX3.9%

NVAX-25.1%

Gross Margin (TTM)

BCRX97.8%

NVAX79.2%

Operating Margin (TTM)

BCRX0.0%

NVAX0.0%

EBITDA Margin (TTM)

BCRX41.1%

NVAX-24.0%

Net Margin (TTM)

BCRX-40.9%

NVAX-59.9%

FCF Margin (TTM)

BCRX41.3%

NVAX-10.4%

Net Income (TTM)

BCRX$-385M

NVAX$-248M

FCF (TTM)

BCRX$388M

NVAX$-43M

EPS (TTM)

BCRX-$1.45

NVAX-$1.51

ROE (TTM)

BCRX-32882.0%

NVAX283.1%

ROA (TTM)

BCRX-7758.0%

NVAX-2275.0%

ROIC (TTM)

BCRX-10666.0%

NVAX40.0%

Cash

BCRX$155M

NVAX$191M

Debt

BCRX$824M

NVAX$297M

Net Cash/Debt

BCRX$-669M

NVAX$-106M

Current Ratio (TTM)

BCRX2.32x

NVAX2.33x

Quick Ratio (TTM)

BCRX2.22x

NVAX2.23x

Debt/Equity (TTM)

BCRX2.26x

NVAX6.07x

Debt/Assets (TTM)

BCRX0.0%

NVAX0.0%

Interest Coverage (TTM)

BCRXN/A

NVAXN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

NVAX0.00x

Beta

BCRX0.54

NVAX2.81

52W Performance

BCRX17.4%

NVAX43.3%

YTD Performance

BCRX14.0%

NVAX78.8%

% from 52W High

BCRX-23.8%

NVAX-4.7%

% from 52W Low

BCRX42.5%

NVAX105.6%

Asset Turnover (TTM)

BCRX1.90x

NVAX0.38x

FCF Yield (TTM)

BCRX17.9%

NVAX-2.0%

Earnings Yield (TTM)

BCRX-17.7%

NVAX-11.8%

Dividend Yield (TTM)

BCRXN/A

NVAXN/A

Rule of 40

BCRX110.0

NVAX-72.0

EV/GP/RG

BCRX0.74

NVAXN/A

Ticker research

View BCRX research View NVAX research

Metric	BCRX BioCryst Pharmaceuticals Inc	NVAX Novavax Inc
Market & Valuation
Market Cap	$2.17B	$2.10B
Enterprise Value	$2.84B	$2.20B
Price	$8.55	$12.75
P/E Ratio	N/A	N/A
P/S Ratio	2.31x	5.07x
EV/Sales	3.02x	5.32x
EV/EBITDA	6.85x	4.05x
P/B Ratio	62.13x	45.86x
P/FCF Ratio	5.59x	N/A
EV/FCF	7.32x	-51.40x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.67x	N/A
Forward P/S (NTM)	3.13x	10.28x
Revenue & Growth
Revenue (TTM)	$941M	$414M
Revenue Growth (YoY)	68.7%	-61.6%
Forward Rev Growth	3.9%	-25.1%
Profitability
Gross Margin (TTM)	97.8%	79.2%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	41.1%	-24.0%
Net Margin (TTM)	-40.9%	-59.9%
FCF Margin (TTM)	41.3%	-10.4%
Net Income (TTM)	$-385M	$-248M
FCF (TTM)	$388M	$-43M
EPS (TTM)	-$1.45	-$1.51
ROE (TTM)	-32882.0%	283.1%
ROA (TTM)	-7758.0%	-2275.0%
ROIC (TTM)	-10666.0%	40.0%
Financial Health
Cash	$155M	$191M
Debt	$824M	$297M
Net Cash/Debt	$-669M	$-106M
Current Ratio (TTM)	2.32x	2.33x
Quick Ratio (TTM)	2.22x	2.23x
Debt/Equity (TTM)	2.26x	6.07x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	2.81
52W Performance	17.4%	43.3%
YTD Performance	14.0%	78.8%
% from 52W High	-23.8%	-4.7%
% from 52W Low	42.5%	105.6%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.38x
FCF Yield (TTM)	17.9%	-2.0%
Earnings Yield (TTM)	-17.7%	-11.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	-72.0
EV/GP/RG	0.74	N/A
Ticker research	View BCRX research	View NVAX research

Valuation

P/S Ratio

BCRX

2.31x

NVAX

5.07x

EV/FCF

NVAX

-51.40x

BCRX

7.32x

Growth & revenue

Revenue Growth TTM

BCRX

68.7%

NVAX

-61.6%

Forward Revenue Growth

BCRX

3.9%

NVAX

-25.1%

Profitability & performance

Gross Margin

BCRX

97.8%

NVAX

79.2%

ROE

NVAX

283.1%

BCRX

-32882.0%

FCF Yield %

BCRX

17.9%

NVAX

-2.0%

52-Week Performance

NVAX

43.3%

BCRX

17.4%

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

NVAX

Novavax Inc

Market Cap

BCRX$2.17B

NVAX$2.10B

Enterprise Value

BCRX$2.84B

NVAX$2.20B

Price

BCRX$8.55

NVAX$12.75

P/E Ratio

BCRXN/A

NVAXN/A

P/S Ratio

BCRX2.31x

NVAX5.07x

EV/Sales

BCRX3.02x

NVAX5.32x

EV/EBITDA

BCRX6.85x

NVAX4.05x

P/B Ratio

BCRX62.13x

NVAX45.86x

P/FCF Ratio

BCRX5.59x

NVAXN/A

EV/FCF

BCRX7.32x

NVAX-51.40x

PEG Ratio

BCRXN/A

NVAXN/A

Forward P/E (NTM)

BCRX16.67x

NVAXN/A

Forward P/S (NTM)

BCRX3.13x

NVAX10.28x

Revenue (TTM)

BCRX$941M

NVAX$414M

Revenue Growth (YoY)

BCRX68.7%

NVAX-61.6%

Forward Rev Growth

BCRX3.9%

NVAX-25.1%

Gross Margin (TTM)

BCRX97.8%

NVAX79.2%

Operating Margin (TTM)

BCRX0.0%

NVAX0.0%

EBITDA Margin (TTM)

BCRX41.1%

NVAX-24.0%

Net Margin (TTM)

BCRX-40.9%

NVAX-59.9%

FCF Margin (TTM)

BCRX41.3%

NVAX-10.4%

Net Income (TTM)

BCRX$-385M

NVAX$-248M

FCF (TTM)

BCRX$388M

NVAX$-43M

EPS (TTM)

BCRX-$1.45

NVAX-$1.51

ROE (TTM)

BCRX-32882.0%

NVAX283.1%

ROA (TTM)

BCRX-7758.0%

NVAX-2275.0%

ROIC (TTM)

BCRX-10666.0%

NVAX40.0%

Cash

BCRX$155M

NVAX$191M

Debt

BCRX$824M

NVAX$297M

Net Cash/Debt

BCRX$-669M

NVAX$-106M

Current Ratio (TTM)

BCRX2.32x

NVAX2.33x

Quick Ratio (TTM)

BCRX2.22x

NVAX2.23x

Debt/Equity (TTM)

BCRX2.26x

NVAX6.07x

Debt/Assets (TTM)

BCRX0.0%

NVAX0.0%

Interest Coverage (TTM)

BCRXN/A

NVAXN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

NVAX0.00x

Beta

BCRX0.54

NVAX2.81

52W Performance

BCRX17.4%

NVAX43.3%

YTD Performance

BCRX14.0%

NVAX78.8%

% from 52W High

BCRX-23.8%

NVAX-4.7%

% from 52W Low

BCRX42.5%

NVAX105.6%

Asset Turnover (TTM)

BCRX1.90x

NVAX0.38x

FCF Yield (TTM)

BCRX17.9%

NVAX-2.0%

Earnings Yield (TTM)

BCRX-17.7%

NVAX-11.8%

Dividend Yield (TTM)

BCRXN/A

NVAXN/A

Rule of 40

BCRX110.0

NVAX-72.0

EV/GP/RG

BCRX0.74

NVAXN/A

Ticker research

View BCRX research View NVAX research

Metric	BCRX BioCryst Pharmaceuticals Inc	NVAX Novavax Inc
Market & Valuation
Market Cap	$2.17B	$2.10B
Enterprise Value	$2.84B	$2.20B
Price	$8.55	$12.75
P/E Ratio	N/A	N/A
P/S Ratio	2.31x	5.07x
EV/Sales	3.02x	5.32x
EV/EBITDA	6.85x	4.05x
P/B Ratio	62.13x	45.86x
P/FCF Ratio	5.59x	N/A
EV/FCF	7.32x	-51.40x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.67x	N/A
Forward P/S (NTM)	3.13x	10.28x
Revenue & Growth
Revenue (TTM)	$941M	$414M
Revenue Growth (YoY)	68.7%	-61.6%
Forward Rev Growth	3.9%	-25.1%
Profitability
Gross Margin (TTM)	97.8%	79.2%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	41.1%	-24.0%
Net Margin (TTM)	-40.9%	-59.9%
FCF Margin (TTM)	41.3%	-10.4%
Net Income (TTM)	$-385M	$-248M
FCF (TTM)	$388M	$-43M
EPS (TTM)	-$1.45	-$1.51
ROE (TTM)	-32882.0%	283.1%
ROA (TTM)	-7758.0%	-2275.0%
ROIC (TTM)	-10666.0%	40.0%
Financial Health
Cash	$155M	$191M
Debt	$824M	$297M
Net Cash/Debt	$-669M	$-106M
Current Ratio (TTM)	2.32x	2.33x
Quick Ratio (TTM)	2.22x	2.23x
Debt/Equity (TTM)	2.26x	6.07x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	2.81
52W Performance	17.4%	43.3%
YTD Performance	14.0%	78.8%
% from 52W High	-23.8%	-4.7%
% from 52W Low	42.5%	105.6%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.38x
FCF Yield (TTM)	17.9%	-2.0%
Earnings Yield (TTM)	-17.7%	-11.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	-72.0
EV/GP/RG	0.74	N/A
Ticker research	View BCRX research	View NVAX research